Selected research
Market Structure
Global Mesenchymal Stem Cell Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Mesenchymal Stem Cell market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Mesenchymal Stem Cell is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Mesenchymal Stem Cell is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Mesenchymal Stem Cell is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Mesenchymal Stem Cell is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Mesenchymal Stem Cell include Takeda, Stempeutics, Pharmicell, Osiris Therapeutics, Medipost, JCR Pharmaceuticals, CHIESI Farmaceutici and Anterogen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Mesenchymal Stem Cell market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Mesenchymal Stem Cell and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Mesenchymal Stem Cell sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Mesenchymal Stem Cell market size, projected growth trends, production technologies, key applications, and end-use industries.
Mesenchymal Stem Cell Segment by Company
Takeda
Stempeutics
Pharmicell
Osiris Therapeutics
Medipost
JCR Pharmaceuticals
CHIESI Farmaceutici
Anterogen
Mesenchymal Stem Cell Segment by Type
Autologous Source
Allogeneic Source
Mesenchymal Stem Cell Segment by Application
Tissue Repair
Immunomodulation
Mesenchymal Stem Cell Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mesenchymal Stem Cell market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mesenchymal Stem Cell and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mesenchymal Stem Cell.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Mesenchymal Stem Cell market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mesenchymal Stem Cell manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Mesenchymal Stem Cell in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Mesenchymal Stem Cell in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Autologous Source
- Allogeneic Source
Applications
- Tissue Repair
- Immunomodulation
Companies covered
- Takeda
- Stempeutics
- Pharmicell
- Osiris Therapeutics
- Medipost
- JCR Pharmaceuticals
- CHIESI Farmaceutici
- Anterogen
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Mesenchymal Stem Cell Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Mesenchymal Stem Cell Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Mesenchymal Stem Cell Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Mesenchymal Stem Cell Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Mesenchymal Stem Cell Market Dynamics
- 2.1 Mesenchymal Stem Cell Industry Trends
- 2.2 Mesenchymal Stem Cell Industry Drivers
- 2.3 Mesenchymal Stem Cell Industry Opportunities and Challenges
- 2.4 Mesenchymal Stem Cell Industry Restraints
3 Mesenchymal Stem Cell Market by Manufacturers
- 3.1 Global Mesenchymal Stem Cell Revenue by Manufacturers (2021-2026)
- 3.2 Global Mesenchymal Stem Cell Sales by Manufacturers (2021-2026)
- 3.3 Global Mesenchymal Stem Cell Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Mesenchymal Stem Cell Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Mesenchymal Stem Cell Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Mesenchymal Stem Cell Manufacturers, Product Type & Application
- 3.7 Global Mesenchymal Stem Cell Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Mesenchymal Stem Cell Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Mesenchymal Stem Cell Players Market Share by Revenue in 2025
- 3.8.3 2025 Mesenchymal Stem Cell Tier 1, Tier 2, and Tier 3
4 Mesenchymal Stem Cell Market by Type
- 4.1 Mesenchymal Stem Cell Type Introduction
- 4.1.1 Autologous Source
- 4.1.2 Allogeneic Source
- 4.2 Global Mesenchymal Stem Cell Sales by Type
- 4.2.1 Global Mesenchymal Stem Cell Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Mesenchymal Stem Cell Sales by Type (2021-2032)
- 4.2.3 Global Mesenchymal Stem Cell Sales Market Share by Type (2021-2032)
- 4.3 Global Mesenchymal Stem Cell Revenue by Type
- 4.3.1 Global Mesenchymal Stem Cell Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Mesenchymal Stem Cell Revenue by Type (2021-2032)
- 4.3.3 Global Mesenchymal Stem Cell Revenue Market Share by Type (2021-2032)
5 Mesenchymal Stem Cell Market by Application
- 5.1 Mesenchymal Stem Cell Application Introduction
- 5.1.1 Tissue Repair
- 5.1.2 Immunomodulation
- 5.2 Global Mesenchymal Stem Cell Sales by Application
- 5.2.1 Global Mesenchymal Stem Cell Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Mesenchymal Stem Cell Sales by Application (2021-2032)
- 5.2.3 Global Mesenchymal Stem Cell Sales Market Share by Application (2021-2032)
- 5.3 Global Mesenchymal Stem Cell Revenue by Application
- 5.3.1 Global Mesenchymal Stem Cell Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Mesenchymal Stem Cell Revenue by Application (2021-2032)
- 5.3.3 Global Mesenchymal Stem Cell Revenue Market Share by Application (2021-2032)
6 Global Mesenchymal Stem Cell Sales by Region
- 6.1 Global Mesenchymal Stem Cell Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Mesenchymal Stem Cell Sales by Region (2021-2032)
- 6.2.1 Global Mesenchymal Stem Cell Sales by Region (2021-2026)
- 6.2.2 Global Mesenchymal Stem Cell Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Mesenchymal Stem Cell Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Mesenchymal Stem Cell Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Mesenchymal Stem Cell Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Mesenchymal Stem Cell Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Mesenchymal Stem Cell Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Mesenchymal Stem Cell Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Mesenchymal Stem Cell Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Mesenchymal Stem Cell Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Mesenchymal Stem Cell Revenue by Region
- 7.1 Global Mesenchymal Stem Cell Revenue by Region
- 7.1.1 Global Mesenchymal Stem Cell Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Mesenchymal Stem Cell Revenue by Region (2021-2026)
- 7.1.3 Global Mesenchymal Stem Cell Revenue by Region (2027-2032)
- 7.1.4 Global Mesenchymal Stem Cell Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Mesenchymal Stem Cell Revenue (2021-2032)
- 7.2.2 North America Mesenchymal Stem Cell Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Mesenchymal Stem Cell Revenue (2021-2032)
- 7.3.2 Europe Mesenchymal Stem Cell Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Mesenchymal Stem Cell Revenue (2021-2032)
- 7.4.2 Asia-Pacific Mesenchymal Stem Cell Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Mesenchymal Stem Cell Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Mesenchymal Stem Cell Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Takeda
- 8.1.1 Takeda Company Information
- 8.1.2 Takeda Business Overview
- 8.1.3 Takeda Mesenchymal Stem Cell Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Takeda Mesenchymal Stem Cell Product Portfolio
- 8.1.5 Takeda Recent Developments
- 8.2 Stempeutics
- 8.2.1 Stempeutics Company Information
- 8.2.2 Stempeutics Business Overview
- 8.2.3 Stempeutics Mesenchymal Stem Cell Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Stempeutics Mesenchymal Stem Cell Product Portfolio
- 8.2.5 Stempeutics Recent Developments
- 8.3 Pharmicell
- 8.3.1 Pharmicell Company Information
- 8.3.2 Pharmicell Business Overview
- 8.3.3 Pharmicell Mesenchymal Stem Cell Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Pharmicell Mesenchymal Stem Cell Product Portfolio
- 8.3.5 Pharmicell Recent Developments
- 8.4 Osiris Therapeutics
- 8.4.1 Osiris Therapeutics Company Information
- 8.4.2 Osiris Therapeutics Business Overview
- 8.4.3 Osiris Therapeutics Mesenchymal Stem Cell Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Osiris Therapeutics Mesenchymal Stem Cell Product Portfolio
- 8.4.5 Osiris Therapeutics Recent Developments
- 8.5 Medipost
- 8.5.1 Medipost Company Information
- 8.5.2 Medipost Business Overview
- 8.5.3 Medipost Mesenchymal Stem Cell Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Medipost Mesenchymal Stem Cell Product Portfolio
- 8.5.5 Medipost Recent Developments
- 8.6 JCR Pharmaceuticals
- 8.6.1 JCR Pharmaceuticals Company Information
- 8.6.2 JCR Pharmaceuticals Business Overview
- 8.6.3 JCR Pharmaceuticals Mesenchymal Stem Cell Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 JCR Pharmaceuticals Mesenchymal Stem Cell Product Portfolio
- 8.6.5 JCR Pharmaceuticals Recent Developments
- 8.7 CHIESI Farmaceutici
- 8.7.1 CHIESI Farmaceutici Company Information
- 8.7.2 CHIESI Farmaceutici Business Overview
- 8.7.3 CHIESI Farmaceutici Mesenchymal Stem Cell Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 CHIESI Farmaceutici Mesenchymal Stem Cell Product Portfolio
- 8.7.5 CHIESI Farmaceutici Recent Developments
- 8.8 Anterogen
- 8.8.1 Anterogen Company Information
- 8.8.2 Anterogen Business Overview
- 8.8.3 Anterogen Mesenchymal Stem Cell Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Anterogen Mesenchymal Stem Cell Product Portfolio
- 8.8.5 Anterogen Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Mesenchymal Stem Cell Value Chain Analysis
- 9.1.1 Mesenchymal Stem Cell Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Mesenchymal Stem Cell Production Mode & Process
- 9.2 Mesenchymal Stem Cell Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Mesenchymal Stem Cell Distributors
- 9.2.3 Mesenchymal Stem Cell Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst